澳大利亚CSL Biotherapies  
CSL Biotherapies的美国总部位于宾夕法尼亚州的普鲁士王（King of Prussia）市；其位于澳大利亚墨尔本市的母公司CSL Limited拥有世界上最大的流感疫苗生产基地之一，可向全球市场供货。CSL Biotherapies向全球营销流感疫苗产品，它与子公司CSL Behring共用美国总部的办公场所。在CSL Biotherapies公司，我们的使命是生产疫苗，我们的激情在于呵护生命。CSL集团还包括CSL Research & Development、CSL Bioplasma以及CSL Behring等部门或子公司，它拥有8600多名员工，在全球27个国家开展业务。
CSL集团包括CSL Bioplasma、CSL Biotherapies以及CSL Behring并购的ZLB Plasma公司。CSL的主要生产基地位于澳大利亚、德国、瑞士与美国境内，它在27个国家共雇用了8600多名员工。
 

CSL Biotherapies manufactures, sells and distributes influenza vaccine worldwide.

CSL Biotherapies draws on the combined heritage and expertise of the CSL Group in the United States, Europe, Asia, Australia and New Zealand to provide safe and reliable products to our customers.
In Australia, CSL Biotherapies markets a comprehensive range of Vaccines and Antivenoms as well as a range of pharmaceutical products supplied by other manufacturers.
CSL Biotherapies understands the influenza vaccine business and customers’ needs for reliable and safe flu vaccine supplies. Our long-established parent, CSL Limited, has been producing flu vaccine without disruption for nearly four decades. Based in Melbourne, Australia, CSL provides flu vaccine to Australia, New Zealand, and more than 16 countries in Europe, South America and Asia.

Beginning with the 2007-2008 season, CSL Biotherapies has been contributing to meeting the growing demand in the United States for reliable supplies of flu vaccine each year. CSL Biotherapies is ideally positioned to become a reliable resource for healthcare professionals who actively embrace the United States government’s flu immunization recommendations.

Millions of people outside the United States already rely on CSL for their flu vaccine. CSL Biotherapies offers several competitive advantages to health care professionals in search of timely delivery of high-quality flu vaccines.